Clinical Effectiveness of Idarucizumab in Dabigatran Reversal | Wang | Journal of Cardiology and Therapy
Praxbind Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis - MPR
Idarucizumab | Circulation
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects - ScienceDirect
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study | SpringerLink
Idarucizumab dosing in patients with excessive dabigatran body burden - British Journal of Anaesthesia
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - ScienceDirect
Idarucizumab for Dabigatran Reversal | NEJM
Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French phar
Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab (PRAXBIND) | STROKE MANUAL
Idarucizumab, the Sequel – Emergency Medicine Literature of Note
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study | SpringerLink
Usefulness of initial plasma dabigatran concentration to predict rebound after reversal | Haematologica
Design of the Reversal Effects of Idarucizumab on Active Dabigatran... | Download Scientific Diagram
Idarucizumab (PRAXBIND) | STROKE MANUAL
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination - Stephan Glund, Guanfa Gan, Viktoria Moschetti, Paul Reilly, Markus Honickel, Oliver Grottke, Joanne Van Ryn,
